Digging into the Sickle Cell landscape with competing therapies Oxbryta (voxelotor) and ADAKVEO (crizanlizumab)Ticker(s): GBT, GLYC, NVS, BLUE, PFE
Name: Dr John Strouse - MD
Institution: Duke University
- Associate Professor of Medicine and Pediatrics and Director of the Adult Sickle Cell Program at Duke University.
- Currently cares for 200 patients with Sickle Cell Disease (100 children & 100 adults) and15 patients with hereditary hemochromatosis.
- Research has focused on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials; local site co-investigator on trials for GBT-440 and rivapansel.
Questions from STAT's Adam Feuerstein to come!Added By: c_admin
Many of the next generation of SCD therapies focus on HbF induction. What magnitude of change in HbF do you believe is required for oral small molecule drugs to be useful and is it relative or absolute HbF change that is more important?Added By: userdd8d73b3
Do you believe there will be wider adoption of Adakveo over Oxybryta, or vice versa? What will be the major drivers for a clinician to prescribe one over the other?Added By: bbresearch
Following the approvals of Adakveo and Oxbryta, what remains the unmet need for SCD patients? What gaps and opportunities remain that drugs in development could address?Added By: bbresearch
RE: VOX- whats the tolerability in real world, of 5 pills per dayAdded By: rhoffman
Thoughts on gene therapies in development for SCD?Added By: bbresearch
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.